Futura Medical Announces Agreement With Haleon To Commercialise MED3000 In The USA
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology, focused on sexual health, today announces that it has entered into a ground breaking licensing agreement with Haleon plc (“Haleon”), a world leading consumer healthcare Company for the rights to exclusively commercialise the Company’s innovative topical, gel-based Erectile Dysfunction (“ED”) treatment MED3000, in the USA.
